FMP
LakeShore Biopharma Co., Ltd.
LSBPW
NASDAQ
LakeShore Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
0.0357 USD
-0.0123 (-34.45%)
LSBPW Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-295.23M
-182.47M
-613.23k
-246.61M
Net Income
-433.46M
-145.48M
-545.73k
-191.83M
Depreciation & Amortization
42.19M
36.69M
31.15M
27.91M
Deferred Income Taxes
-21.73M
1.13M
4.94M
17.45M
Stock Based Compensation
9.79M
3.51M
7.76M
76.76M
Change in Working Capital
-45.79M
-92.75M
-64.05k
-186.68M
Accounts Receivable
13.9M
-165.25M
-99.14M
-220.73M
Inventory
-86.26M
-18.15M
-89.46M
-68.73M
Accounts Payable
-12.66M
49.63M
14.43M
-4.42M
Other Working Capital
39.23M
-6.45M
-64.05k
-44.29k
Other Non-Cash Items
153.78M
4.42M
-3.45k
2.23M
CF from Investing Activities
-44.25M
-56.98M
-200M
-104.24M
Investments in Property, Plant & Equipment
-44.25M
-57.05M
-298.93M
-104.88M
Net Acquisitions
0
0
0
0
Investment Purchases
0
0
-200M
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
0
0
0
0
CF from Financing Activities
205.26M
317.45M
201.5M
739.26M
Debt Repayment
-78.93M
100.88M
364.56M
8.26M
Common Stock Issued
284.2M
0
201.86M
1.59M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
0
216.57M
-163.06M
729.41M
Free Cash Flow
-339.48M
-239.52M
-299.55M
-351.49M
Operating Cash Flow
-295.23M
-182.47M
-613.23k
-246.61M
Capital Expenditures
-44.25M
-57.05M
-298.93M
-104.88M
Cash at Beginning of Period
370.37M
271.07M
390.46M
2.05M
Cash at End of Period
246.55M
370.37M
885.2k
390.46M
Net Change In Cash
-123.82M
99.3M
-389.57M
388.41M
Retained Earning Schedule
Year
2024
2023
2022
Retained Earnings (Previous Year)
-1.87B
-19.32M
-3.64k
Net Income
-433.46M
-145.48M
-545.73k
Stock Repurchases
0
0
0
Dividend Paid
0
0
0
Retained Earnings
-2.31B
-1.87B
-19.32M
Other Distributions
-433.46M
-1.85B
-19.31M
PPE Schedule
Year
2024
2023
2022
Gross PPE
480.62M
582.89M
565M
Annual Depreciation
42.19M
36.69M
31.15M
Capital Expenditure
-44.25M
-57.05M
-298.93M
Net PPE
482.69M
603.25M
832.78M
Intangible and Goodwill Schedule
Year
2024
2023
2022
Acquisitions and Adjustments
0
0
0
Goodwill (Previous Year)
0
0
0
Goodwill
0
0
0
All figures are in CNY.
